N-(3-chloropropyl)dibutylamine

We are N-(3-chloropropyl)dibutylamine CAS:36421-15-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N-(3-chloropropyl)dibutylamine
CAS.NO:36421-15-5
Synonyms:
N-Butyl-N-(3-chloropropyl)butan-1-amine

Molecular Formula:C11H24ClN
Molecular Weight:205.76800

Physical and Chemical Properties:
Density: 0.899g / cm3
Boiling point: 253.2ºC at 760mmHg
Melting point: /
Flash point: 106.9ºC
Refractive index: 1.45

Specification:
Appearance:Light yellow to colorless liquid
Purity:≥98%
Water content:≤1.0%
Any impurity: 0.5%max

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Dronedarone hydrochloride CAS:141625-93-6
Intermediates of Dronedarone CAS:141626-36-0

N-(3-chloropropyl)dibutylamine


Related News: We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently.Ortosilicato de tetrabutilo CAS:4766-57-8 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.5-bromo-7,7-dimetilbenzo [c] fluoreno CAS:954137-48-5 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.3335-46-4 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.

Related Products
Product Name
4-Bromotoluene View Details
5-amino-1-(N-methylcarbamoyl)imidazole-4-carboxamide View Details
2,5-Dibromo-4-methylpyridine View Details
Diethoxymethylsilane manufacturer L-Alanyl-L-Glutamine manufacturer 4-Carboxy-3-fluorophenylboronic acid manufacturer 2-[(Diphenylmethyl)Thio]Acetamide manufacturer N-Boc-D-cyclohexylglycinol manufacturer